Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WHIP3TB: High-dose Rifapentine + Isoniazid in HIV-positive Individuals
NCT02980016Phase 3Completed
- Sponsor
- Aurum Institute
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifapentine in Tuberculosis (TB), sponsored by Aurum Institute. Started Nov 2016; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02980016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980016.